JP2024544520A5 - - Google Patents

Info

Publication number
JP2024544520A5
JP2024544520A5 JP2024527384A JP2024527384A JP2024544520A5 JP 2024544520 A5 JP2024544520 A5 JP 2024544520A5 JP 2024527384 A JP2024527384 A JP 2024527384A JP 2024527384 A JP2024527384 A JP 2024527384A JP 2024544520 A5 JP2024544520 A5 JP 2024544520A5
Authority
JP
Japan
Prior art keywords
amino acid
region
seq
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024527384A
Other languages
English (en)
Japanese (ja)
Other versions
JP7861115B2 (ja
JP2024544520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/081225 external-priority patent/WO2023083846A1/en
Publication of JP2024544520A publication Critical patent/JP2024544520A/ja
Publication of JP2024544520A5 publication Critical patent/JP2024544520A5/ja
Application granted granted Critical
Publication of JP7861115B2 publication Critical patent/JP7861115B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024527384A 2021-11-10 2022-11-09 抗体分子及び複合体 Active JP7861115B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263835P 2021-11-10 2021-11-10
US63/263,835 2021-11-10
PCT/EP2022/081225 WO2023083846A1 (en) 2021-11-10 2022-11-09 Antibody molecules and conjugates

Publications (3)

Publication Number Publication Date
JP2024544520A JP2024544520A (ja) 2024-12-03
JP2024544520A5 true JP2024544520A5 (cg-RX-API-DMAC7.html) 2025-10-20
JP7861115B2 JP7861115B2 (ja) 2026-05-18

Family

ID=84387847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527384A Active JP7861115B2 (ja) 2021-11-10 2022-11-09 抗体分子及び複合体

Country Status (15)

Country Link
US (2) US12065496B2 (cg-RX-API-DMAC7.html)
EP (1) EP4429765A1 (cg-RX-API-DMAC7.html)
JP (1) JP7861115B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240099430A (cg-RX-API-DMAC7.html)
CN (1) CN118556084A (cg-RX-API-DMAC7.html)
AR (1) AR127629A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022384597B2 (cg-RX-API-DMAC7.html)
CA (1) CA3237211A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001384A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007192A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP24044371A (cg-RX-API-DMAC7.html)
IL (1) IL312566A (cg-RX-API-DMAC7.html)
MX (1) MX2024005712A (cg-RX-API-DMAC7.html)
TW (1) TW202336037A (cg-RX-API-DMAC7.html)
WO (1) WO2023083846A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525410A (ja) * 2022-06-27 2025-08-05 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ
CN122161833A (zh) * 2023-11-15 2026-06-05 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
IL328594A (en) 2023-11-23 2026-07-01 Velavigo Bio Inc Binding molecule and antibody-drug conjugate and their uses
CN117659203B (zh) * 2023-12-06 2024-08-13 科弈(浙江)药业科技有限公司 一种抗met/egfr双特异性抗体及其药物偶联物
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
TW202608928A (zh) * 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體藥物偶聯物
TW202608927A (zh) * 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體-藥物偶聯物
WO2026021476A1 (en) 2024-07-24 2026-01-29 Beone Guangzhou Biologics Manufacturing Co., Ltd. Anti-cmet and anti-egfr multispecific antibody drug conjugates
CN121868507A (zh) * 2024-10-16 2026-04-17 上海安领科生物医药有限公司 抗EGFR和cMET双特异性抗体的抗体药物偶联物
WO2026086737A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases
WO2026086740A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use and method of bispecific antibody-drug conjugates for treating tumor diseases
WO2026086844A1 (zh) * 2024-10-23 2026-04-30 正大天晴药业集团股份有限公司 靶向EGFR和c-Met的抗体药物偶联物
WO2026098440A1 (zh) * 2024-11-05 2026-05-15 上海齐鲁制药研究中心有限公司 一种双特异性抗体偶联物及其制备方法和应用
WO2026124468A1 (en) * 2024-12-10 2026-06-18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pharmaceutical combinations, their uses and therapeutic methods
WO2026145588A1 (en) 2024-12-31 2026-07-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use of egfr/c-met bispecific binding protein
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2026150367A1 (en) * 2025-01-13 2026-07-16 Janssen Biotech, Inc. Bispecific anti-egfr/c-met antibody-drug conjugates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP1521769B1 (de) 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
US8889880B2 (en) 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
CA2945318A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Tubulysin derivatives
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
EP3630844A4 (en) 2017-05-30 2021-03-03 Chong Kun Dang Pharmaceutical Corp. NOVEL ANTI-C-MET ANTIBODY AND USE OF IT

Similar Documents

Publication Publication Date Title
JP7118117B2 (ja) 抗体-薬物コンジュゲートの選択的製造方法
JP7861115B2 (ja) 抗体分子及び複合体
CN117946274B (zh) 抗cd73抗体及其应用
CN114106190B (zh) 一种抗vegf/pd-l1双特异性抗体及其用途
TWI564306B (zh) 雙特異性抗體
WO2019173832A2 (en) Novel cytokine prodrugs
ES3035714T3 (en) Edb targeting il-12 compositions
JP2020537520A5 (cg-RX-API-DMAC7.html)
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
CN114981301B (zh) Pd1和vegfr2双结合剂
CN105209493A (zh) 用于诊断和治疗用途的her3特异性单克隆抗体
JP2020532523A (ja) 抗egfr抗体薬物コンジュゲート(adc)及びその使用
CN115335400A (zh) 结合整合素avb8的抗体及其用途
KR20230171465A (ko) 항cldn4-항cd137 이중특이성 항체
CA3180188A1 (en) Anti-flt3 antibodies and compositions
CN119343378A (zh) 靶向itga2的抗体和包含此抗体的抗体药物缀合物
CN118754989B (zh) 一种抗her2纳米抗体及其制备方法和应用
CN117659194B (zh) 靶向egfr的纳米抗体、药物偶联物及其用途
CN119744272A (zh) 一种抗ror1蛋白的抗体及其缀合物
CN114773485B (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
CN121311503A (zh) 靶向itga2的抗体、其抗体药物缀合物以及用途
WO2025157266A1 (zh) 一种Nectin-4抗体及其应用
WO2026082207A1 (zh) 抗EGFR和cMET双特异性抗体的抗体药物偶联物
CN118994393A (zh) 一种抗fgfr2抗体及其应用
JP2024501739A (ja) ヒトlifr抗原結合タンパク質、その製造方法及び応用